BioArctic (OM:BIOA B) Stock Confronts Leqembi Dependence After Profit Reversal

BioArctic stock comes into this earnings print with a flat month, a weak 7 day stretch and a 90 day slide that has chipped away at recent enthusiasm. The market has cooled on the story just as the Q2 numbers land.

The headline is simple. A biotech built on rich Leqembi royalty expectations has just posted a small quarterly loss despite SEK 247.5m in revenue and recurring royalties closing in on SEK 200m per quarter. The main question now is how investors price a profit wobble in a business still leaning heavily on a single Alzheimer franchise.

Like the BioArctic story but concerned about the reliance on a single royalty stream and recent profit wobble? Check out 611 high quality undiscovered gems

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs Q2 2025: SEK 247.5m vs SEK 392.1m (revenue declined 36.9%)
• Net Income, Q2 2026 vs Q2 2025: loss of SEK 11.2m vs profit of SEK 96.6m (swung from profit to loss)
• Basic EPS, Q2 2026 vs Q2 2025: loss of SEK 0.13 per share vs profit of SEK 1.09 per share (earnings per share moved from profit to loss)
• Pipeline Breadth, Q2 2026 vs Q2 2025: products in Phase II: 1 vs 1; products in Phase III: 1 vs 1; and no products in pre registration in Q2 2026 compared with 1 in Q2 2025

Prefer clear visuals over long earnings tables and footnotes? View BioArctic's full financial picture, including a straightforward look at its earnings trend related to Leqembi royalties, in the interactive company report for BioArctic.

BioArctic Bull Case Hinges On Executing Leqembi And Platform Plan

Bulls argue BioArctic can turn Leqembi into a reliable cash engine and use BrainTransporter to build a broader neurology and oncology business. Q2 shows parts of that playbook actually progressing. Leqembi royalties reached SEK 179.4m and are now close to SEK 200m in recurring quarterly revenue, while Eisai kept full year Leqembi sales guidance and BioArctic still targets full year 2026 profitability despite a small Q2 loss.

The second leg of the bullish story is platform leverage. Here, investors did get concrete milestones. The Eli Lilly BrainTransporter collaboration is in place with a US$30m upfront already boosting post quarter cash, and the Mesenkia deal takes BrainTransporter into glioblastoma, BioArctic’s first oncology step. Combined with a solid cash balance above SEK 2.3b after July, the company is at least funding and signing on to the multi program, multi partner future that the bull case expects.

Reveal where the surface looks calm, but the multi year models for BioArctic start to diverge from today's SEK325.4 share price. Access the analyst estimates for BioArctic.

BioArctic Bear Fears On Concentration And Volatility Tested

Bears argue BioArctic is overexposed to a single Alzheimer royalty stream and that earnings will be volatile when partners or payers hesitate. Q2 does give some support to that worry. Revenue fell 36.9% year on year to SEK 247.5m as a 2025 milestone dropped out, and the company moved from a SEK 96.6m profit to an SEK 11.2m loss despite Leqembi royalties of SEK 179.4m. That shows how dependent the income statement is on non recurring items and partner timing.

The other bearish claim is that rising spend will erode margins before diversification pays off. Operating costs climbed as R&D stepped up, and management guides to a 40% to 60% increase in full year 2026 operating expenses. New BrainTransporter deals with Eli Lilly and Mesenkia broaden the opportunity set, but they are still early and do not yet offset the concentration and earnings volatility that bears focus on.

Review whether BioArctic’s profit swing and royalty dependence are isolated issues or early warning signs. Scan the independent risk analysis for BioArctic which shows 1 important warning sign.

Stay Ahead With Simply Wall St

If the mix of strong Leqembi royalties and a recent profit wobble has put BioArctic on your radar, register for free with Simply Wall St and add it to a Watchlist so you can track the share price against fair value and watch for a more attractive entry point. Once you are invested, keep your view clear with the Portfolio Command Center that cuts through market noise and surfaces only the key developments that matter to your holdings. For a broader perspective, tap into shared research and sentiment through the Community and see how other investors are thinking about BioArctic and similar stocks. With these tools working together, you can monitor catalysts and potential risks more closely and stay a step ahead of the market.

Seeking Alternatives Beyond BioArctic Now

Some stocks only show their breakout potential briefly. Use fresh screeners to spot momentum while it matters, before stories get crowded or drop from view. Act now.

• Spot cash generative companies with room to move by scanning the curated 271 high quality undervalued stocks that still sit under the radar for now.
• Ride structural demand in critical materials by reviewing the focused 31 best rare earth metal stocks and see which producers could benefit if sentiment starts flying.
• Target reliable cash flows while markets stay restless by shortlisting payouts from the hand picked 411 dividend fortresses before yields get compressed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com